19 min
Rundown: What Changed in the GRAPPA Guidelines for Psoriatic Arthritis? Medscape InDiscussion: Psoriatic Arthritis
-
- Science
Experts Stanley Cohen and Arthur Kavanaugh give busy clinicians a rundown of what's new and noteworthy in the 2021 GRAPPA guidelines update.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984267). The topics and discussions are planned, produced, and reviewed independently of the advertisers. This podcast is intended only for US healthcare professionals.
Resources
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated Treatment Recommendations for Psoriatic Arthritis 2021 https://pubmed.ncbi.nlm.nih.gov/35761070/
Etanercept Treatment of Psoriatic Arthritis: Safety, Efficacy, and Effect on Disease Progression https://pubmed.ncbi.nlm.nih.gov/15248226/
GRADE: An Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations https://pubmed.ncbi.nlm.nih.gov/18436948/
US Welcomes First Adalimumab Biosimilar, Amjevita https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Impact of Clinical Domains Other Than Arthritis on Composite Outcomes in Psoriatic Arthritis: Comparison of Treatment Effects in the SEAM-PsA Trial https://pubmed.ncbi.nlm.nih.gov/35863864/
Experts Stanley Cohen and Arthur Kavanaugh give busy clinicians a rundown of what's new and noteworthy in the 2021 GRAPPA guidelines update.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984267). The topics and discussions are planned, produced, and reviewed independently of the advertisers. This podcast is intended only for US healthcare professionals.
Resources
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated Treatment Recommendations for Psoriatic Arthritis 2021 https://pubmed.ncbi.nlm.nih.gov/35761070/
Etanercept Treatment of Psoriatic Arthritis: Safety, Efficacy, and Effect on Disease Progression https://pubmed.ncbi.nlm.nih.gov/15248226/
GRADE: An Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations https://pubmed.ncbi.nlm.nih.gov/18436948/
US Welcomes First Adalimumab Biosimilar, Amjevita https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Impact of Clinical Domains Other Than Arthritis on Composite Outcomes in Psoriatic Arthritis: Comparison of Treatment Effects in the SEAM-PsA Trial https://pubmed.ncbi.nlm.nih.gov/35863864/
19 min